OLAPARIB

Brand name:

• Lynparza®

Pharmaceutical company:

AstraZeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Breast cancer

PBAC Submission type:

New PBS listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2023

Related medicines:

--

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---